The effects of direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) 
Introduction
Recently, it was reported that some new drugs, in particular, lefulunomide, which belongs to a new class of diseasemodifying antirheumatic drugs (1) , and gefitinib, a new molecular agent targeting lung cancer (2) , can induce severe interstitial lung disease. There are also some reports of severe respiratory failure or acute respiratory distress syndrome (ARDS) resulting from the use of other drugs, such as methotrexate (MTX) (3) , and certain herbal medicines (4, 5) .
In general, discontinuance of the original drug is standard therapy for drug-induced cases of interstitial lung disease (DI-ILD) (3) . Some studies have reported that corticosteroid therapy is effective for DI-ILD; (6) however, steroid therapy alone is inadequate for the treatment of certain conditions. There is no advanced treatment strategy established for severe DI-ILD in cases wherein corticosteroid therapy is ineffective. In the case of idiopathic interstitial pneumonia, cyclophosphamide (7) and cyclosporin (8) 
Case Report

General management of DI-ILD
First, we discontinued the original drug that caused DI-ILD. As a standard therapy, the patient was treated with high-dose corticosteroid therapy (1 g/d of methylpredniso-T a b l e 1 . Ch a r a c t e r i s t i c s a n d Ou t c o me o f P MX-DHP T r e a t me n t i n t h e P a t i e n t s (Fig. 1) .
The protocol for PMX-DHP treatment was approved by the Human Ethics Review Committee of Shinshu University School of Medicine. The patients or their families provided written informed consent before PMX-DHP treatment.
The characteristics and outcomes of PMX-DHP in the patients were shown in Table 1 .
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Case 1
A (Fig. 3) .
Case 3
A 65-year-old man was diagnosed with acute pneumonia and treated with antibiotic therapy in another hospital. However, it did not improve his condition, and high-dose corticosteroid therapy was initiated. Then, he was admitted to our hospital due to severe hypoxemia. Examination of his past history revealed that he had used herbal medicine, namely, sanmotsu-ogon-to for leg pain 1 month before admission in the previous hospital. He was clinically diag-
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F i g u r e 4 . Ch e s t r a d i o g r a p h s , CT s c a n s , a n d c l i n i c a l c o u r s e o f c a s e 3 . nosed with DI-ILD caused by this herbal medicine, but the DLST could not be conducted because corticosteroid therapy had already been administered in the previous hospital. He required mechanical ventilation and endotracheal intubation due to severe hypoxemia. We could not perform BAL. The P/F ratio had already decreased to 78.6 during the first high-dose corticosteroid therapy in the other hospital. We could not confirm the P/F ratio before the corticosteroid therapy in the previous hospital. However, since the FiO2 level increased and SpO2 level had decreased during corticosteroid therapy, it was suggested that the P/F ratio had decreased. Because of the ineffectiveness of high-dose corticosteroid therapy, PMX-DHP treatment was introduced, and subsequently, his hypoxemia improved. The WBC count; neutrophil numbers; and CRP, serum LDH, and KL-6 levels improved during the 2 d of PMX-DHP treatment. The pa-
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tient was treated with CPA pulse therapy biweekly. On day 66 after admission, he was withdrawn from mechanical ventilation and he survived (Fig. 4) . (11) . We proposed that PMX-DHP treatment would simultaneously improve oxygenation because the production of inflammatory cytokines was suppressed (10, 12) . (12) 
Discussion
We demonstrated the potential beneficial effects of PMX-DHP treatment for DI-ILD patients. PMX-DHP treatment has been used in Japan since 1994 as a treatment for sepsis or septic shock. The PMX column was developed for the adsorption of endotoxins in blood. Originally, PMX-DHP treatment was shown to be effective against sepsis caused by gram-negative rods, and it improved the hemodynamic status. A multicenter clinical study that included many patients with ARDS revealed that the treatment of septic shock with PMX-DHP was associated with a reduction in the concentration of endotoxins, and there was a decrease in the mortality rate (9). Our group reported that PMX-DHP treatment improved both the hemodynamic instability and oxygenation during endotoxemia in anesthetized sheep
The effects of PMX-DHP treatment on acute respiratory failure during interstitial lung disease have not been established. Recently, Seo et al reported that PMX-DHP treatment is effective against acute exacerbation of idiopathic pulmonary fibrosis (IPF) (13). In any case, the pathological finding of acute exacerbation of IPF is diffuse alveolar damage (DAD). However, the mechanism underlying the effect of PMX-DHP treatment in these situations is unclear. In previous reports, PMX-DHP treatment was found to improve the inflammation due to DAD via a decrease in the level of activated neutrophils. Kushi et al
